

	CMS: Addendum B. -- OPPS Payment by HCPCS Code for CY 2026 (updated 07/21/26).								
HCPCS Code	CMS Short Descriptor	SI	APC	CMS Average Lump sum Payment	CMS Average Lump sum Payment	CMS Average Lump sum Payment	Δ in payment (7/9/2025 --> 7/21/2026)	Drug Trade Name	Pharmaceutical Manufacturer

2026 CMS Average Lump-Sum Payment (for Immune Effector Cell therapies):

				7/9/2025	12/29/2025	7/21/2026	Δ in payment		
Q2041	Axicabtagene ciloleucel car+	K	9035	\$533,076.48	\$532,192.24	\$562,500.89	\$29,424.41	*Yescarta	Kite
Q2042	Tisagenlecleucel car-pos t	K	9194	\$578,324.58	\$566,531.30	\$611,693.17	\$33,368.59	*Kymriah	Novartis
Q2043	Sipuleucel-t auto cd54+	K	9273	\$55,945.97	\$54,404.11	\$55,932.43	neg \$13.54	Provenge	Dendreon
Q2053	Brexucabtagene car pos t	K	9391	\$489,720.00	\$489,450.20	\$510,103.92	\$20,383.92	*Tescartus	Kite
Q2054	Lisocabtagene mara car pos t	K	9413	\$541,635.66	\$562,201.24	\$579,570.61	\$37,934.95	**Breyanzi	BMS
Q2055	Idecabtagene vicleucel car	K	9422	\$541,260.45	\$558,081.73	\$567,977.78	\$26,717.33	*Abecma	BMS
Q2056	Ciltacabtagene car-pos t	K	9498	\$553,378.83	\$587,649.57	\$587,977.76	\$34,598.93	*Carvykti	J&J
Q2057	Afamitresgene autoleucel	G	2067	\$770,620.00	\$770,620.00	\$813,967.38	\$43,347.38	Tecelra	USWM
Q2058	Obechtge autol up to 400 mil	G	0831	\$270,375.00	\$278,250.00	\$278,250.00	\$7,875.00	Aucatzyl	Autolus

Change in payment: -\$13.54 to +\$43,347.38 (8 pos./1 neg.): mean Δ in payment: +\$25,960 (over 12+ mos.)	
**Breyanzi: FDA approved for: R/R marginal zone lymphoma (12/4/25); R/R mantle cell lymphoma (5/30/24);	
R/R follicular lymphoma (5/15/24); R/R CLL or SLL (3/14/24); R/R large B-cell lymphoma (2/5/21 and 6/24/22).	
Top 6 CAR T-cell therapies (*and**): mean Δ in payment: +\$30,405 (\$2,452/mo. X 12.4 mos.; increase of 5.64%).	

Average CAR T-cell lump-sum payment (6 of 7 CAR T-cell therapies): ~\$40,000 (07/2025) --> ~\$570,000 (07/2026).

Source of CMS information:

<https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates>

<https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient-pps/quarterly-addenda-updates/july-2026-addendum-b>

Disclaimer: the information provided in this document is for illustrative purposes only, and does not constitute billing, reimbursement, or legal advice. Neither the American Society for Apheresis nor any of its members or supporters makes any representation or warranty concerning this information or its completeness, accuracy, or timeliness. No entity involved in the preparation of this document makes any representation about the likelihood of success in obtaining insurance coverage or reimbursement for any service. It is solely the responsibility of the provider to determine and submit appropriate codes, charges, and other documentation in claims for services rendered. Answers are for general guidance only (as CMS coding and reimbursement policies are subject to change). Copyright ©2026 by the American Society for Apheresis. All rights reserved. July, 2026.